Duration Of Monotherapy
Duration of Monotherapy is a temporal metric denoting the length of time during which a single therapeutic agent is administered as the sole treatment for a condition, distinguishing it from combination or sequential therapies.
81
Publications
5K
Citations
718
Authors
332
Institutions
Publications per year
2017–2026
19
Parents
81
Selegiline slows the progression of the symptoms of Parkinson disease
Sven Pålhagen, E. H. Heinonen, J. Hägglund et al. · Neurology · 2006 · 267 citations
Robert A. Fridell, Chunfu Wang, Jin-Hua Sun et al. · Hepatology · 2010 · 228 citations · Full text
1–5 of 81
718
2
h-index
2
h-index
2
h-index
1 publications · 14 citations
1
h-index
The University of Texas MD Anderson Cancer Center, United States
1 publications · 36 citations
1
h-index
1–5 of 718
332
Bristol-Myers Squibb (United States)
New York, United States
3 h-index
18 publications
3.2K citations
Eli Lilly (United States)
Indianapolis, United States
3 h-index
9 publications
965 citations
Assistance Publique – Hôpitaux de Paris
Paris, France
2 h-index
12 publications
878 citations
United States Military Academy
West Point, United States
2 h-index
12 publications
442 citations
Charles University
Prague, Czechia
2 h-index
3 publications
166 citations

University of Milan
Milan, Italy
2 h-index
2 publications
246 citations

City Of Hope National Medical Center
Duarte, United States
2 h-index
2 publications
60 citations

National and Kapodistrian University of Athens
Athens, Greece
2 h-index
13 publications
173 citations
1–8 of 332
Repository · 7 publications · 210 citations
7
h-index
JAC · 3 publications · 180 citations
3
h-index
3 publications · 536 citations
3
h-index
3 publications · 239 citations
3
h-index
JID · 2 publications · 152 citations
2
h-index
1–5